Monoclonal Antibody Analysis of Neutralization and Antibody-dependent Enhancement of Feline Infectious Peritonitis Virus
Overview
Authors
Affiliations
Fifty-four monoclonal antibodies (MAbs) to feline infectious peritonitis virus (FIPV) were characterized according to protein specificity, immunoglobulin subclass, virus neutralization, reactivity with different coronaviruses, and ability to induce antibody-dependent enhancement (ADE) of FIPV infection in vitro. The MAbs were found to be specific for one of three structural proteins of FIPV. A total of 47 MAbs were specific for the 205-kDa spike protein (S), 3 MAbs were specific for the 45-kDa nucleocapsid protein (N), and 4 MAbs were specific for the 26- to 28-kDa membrane protein (M). The S-specific MAbs showed various degrees of cross-reactivity with strains of FIPV, feline enteric coronavirus, canine coronavirus, and porcine transmissible gastroenteritis virus. Nineteen S-specific MAbs neutralized FIPV. A total of 15 of the neutralizing MAbs induced ADE, and all but 1 were of the immunoglobulin G2a subclass. The remaining four neutralizing MAbs that did not induce ADE were of the immunoglobulin G1 subclass. Two S-specific MAbs induced ADE but were nonneutralizing. None of the N- or M-specific MAbs was neutralizing or induced ADE. On the basis of the reactivity patterns of the MAbs with FIPV and related coronaviruses, it was concluded that there is a minimum of five neutralizing sites on S. In most instances, neutralizing MAbs were able to induce ADE, demonstrating a direct relationship between neutralization and enhancement. The difference in immunoglobulin subclass between neutralizing MAbs that induced ADE and those that did not induce ADE suggests that there may be a restriction in the immunoglobulin subclasses capable of mediating ADE.
Antibody-dependent enhancement of coronaviruses.
Tao T, Tian L, Ke J, Zhang C, Li M, Xu X Int J Biol Sci. 2025; 21(4):1686-1704.
PMID: 39990674 PMC: 11844293. DOI: 10.7150/ijbs.96112.
Complement Evasion Protects FCoV from Virus Clearance Within Prototypic FIP Lesions.
Honl A, Felten S, Erber K, Bergmann M, Reese S, Hofmann-Lehmann R Viruses. 2024; 16(11).
PMID: 39599800 PMC: 11598988. DOI: 10.3390/v16111685.
Preclinical assessment of a recombinant RBD-Fc fusion protein as SARS-CoV-2 candidate vaccine.
Dashti N, Golsaz-Shirazi F, Soltanghoraee H, Zarnani A, Mohammadi M, Imani D Eur J Microbiol Immunol (Bp). 2024; 14(3):228-242.
PMID: 38753442 PMC: 11393645. DOI: 10.1556/1886.2024.00045.
The "original antigenic sin" and its relevance for SARS-CoV-2 (COVID-19) vaccination.
Rijkers G, van Overveld F Clin Immunol Commun. 2024; 1:13-16.
PMID: 38620690 PMC: 8500682. DOI: 10.1016/j.clicom.2021.10.001.
A One Health Perspective on Canine Coronavirus: A Wolf in Sheep's Clothing?.
Buonavoglia A, Pellegrini F, Decaro N, Galgano M, Pratelli A Microorganisms. 2023; 11(4).
PMID: 37110344 PMC: 10143937. DOI: 10.3390/microorganisms11040921.